145 related articles for article (PubMed ID: 37410796)
1. Initial presentation of early rheumatoid arthritis.
Weman L; Salo H; Kuusalo L; Huhtakangas J; Kärki J; Vähäsalo P; Backström M; Sokka-Isler T
PLoS One; 2023; 18(7):e0287707. PubMed ID: 37410796
[TBL] [Abstract][Full Text] [Related]
2. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
[TBL] [Abstract][Full Text] [Related]
3. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
Mouterde G; Rincheval N; Lukas C; Daien C; Saraux A; Dieudé P; Morel J; Combe B
Arthritis Res Ther; 2019 Jun; 21(1):140. PubMed ID: 31171038
[TBL] [Abstract][Full Text] [Related]
5. Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study.
Choi S; Lee KH
PLoS One; 2018; 13(4):e0195550. PubMed ID: 29624625
[TBL] [Abstract][Full Text] [Related]
6. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
[TBL] [Abstract][Full Text] [Related]
7. Is Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis Still a More Severe Disease Than Anti-Citrullinated Protein Antibody-Negative Rheumatoid Arthritis? A Longitudinal Cohort Study in Rheumatoid Arthritis Patients Diagnosed From 2000 Onward.
Boer AC; Boonen A; van der Helm van Mil AHM
Arthritis Care Res (Hoboken); 2018 Jul; 70(7):987-996. PubMed ID: 29266813
[TBL] [Abstract][Full Text] [Related]
8. ACPA Antibodies Titer at the Time of Rheumatoid Arthritis Diagnosis Is Not Associated with Disease Severity.
Shpatz R; Braun-Moscovici Y; Balbir-Gurman A
Isr Med Assoc J; 2021 Oct; 23(10):646-650. PubMed ID: 34672447
[TBL] [Abstract][Full Text] [Related]
9. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria.
Nordberg LB; Lillegraven S; Lie E; Aga AB; Olsen IC; Hammer HB; Uhlig T; Jonsson MK; van der Heijde D; Kvien TK; Haavardsholm EA;
Ann Rheum Dis; 2017 Feb; 76(2):341-345. PubMed ID: 27094444
[TBL] [Abstract][Full Text] [Related]
10. Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity.
Reed E; Hedström AK; Hansson M; Mathsson-Alm L; Brynedal B; Saevarsdottir S; Cornillet M; Jakobsson PJ; Holmdahl R; Skriner K; Serre G; Alfredsson L; Rönnelid J; Lundberg K
Arthritis Res Ther; 2020 Jul; 22(1):170. PubMed ID: 32678001
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study.
Bird P; Nicholls D; Barrett R; de Jager J; Griffiths H; Roberts L; Tymms K; McCloud P; Littlejohn G;
Int J Rheum Dis; 2017 Apr; 20(4):460-468. PubMed ID: 28205333
[TBL] [Abstract][Full Text] [Related]
12. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
[TBL] [Abstract][Full Text] [Related]
13. Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study.
Alemao E; Bao Y; Weinblatt ME; Shadick N
Arthritis Care Res (Hoboken); 2020 Feb; 72(2):176-183. PubMed ID: 31529682
[TBL] [Abstract][Full Text] [Related]
14. Thyroid disorders in patients with newly diagnosed rheumatoid arthritis is associated with poor initial treatment response evaluated by disease activity score in 28 joints-C-reactive protein (DAS28-CRP): An observational cohort study.
Emamifar A; Hangaard J; Jensen Hansen IM
Medicine (Baltimore); 2017 Oct; 96(43):e8357. PubMed ID: 29069018
[TBL] [Abstract][Full Text] [Related]
15. Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity.
Coffey CM; Crowson CS; Myasoedova E; Matteson EL; Davis JM
Mayo Clin Proc; 2019 Nov; 94(11):2241-2248. PubMed ID: 31619364
[TBL] [Abstract][Full Text] [Related]
16. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
17. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study.
Innala L; Berglin E; Möller B; Ljung L; Smedby T; Södergren A; Magnusson S; Rantapää-Dahlqvist S; Wållberg-Jonsson S
Arthritis Res Ther; 2014 Apr; 16(2):R94. PubMed ID: 24731866
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study.
Boman A; Brink M; Lundquist A; Hansson M; Mathsson-Alm L; Rönnelid J; Berglin E; Holmdahl R; Skriner K; Serre G; Klareskog L; Rantapää-Dahlqvist S
RMD Open; 2019; 5(2):e000946. PubMed ID: 31565241
[TBL] [Abstract][Full Text] [Related]
19. A quarter of patients time their early rheumatoid arthritis onset differently than physicians.
Ellingwood L; Kudaeva F; Schieir O; Bartlett SJ; Bessette L; Boire G; Hazlewood GS; Hitchon C; Keystone E; Tin D; Thorne C; Bykerk VP; Pope J;
RMD Open; 2019; 5(2):e000931. PubMed ID: 31803498
[TBL] [Abstract][Full Text] [Related]
20. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A; Korpela M; Haapala AM; Kautiainen H; Laasonen L; Möttönen T; Leirisalo-Repo M; Ilonen J; Järvenpää S; Luukkainen R; Hannonen P
Clin Exp Rheumatol; 2011; 29(3):500-5. PubMed ID: 21640044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
